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Abstract
Background: Korean mistletoe (Viscum album coloratum) is a semi-parasitic plant that grows on various trees and
has a diverse range of effects on biological functions, being implicated in having anti-tumor, immunostimulatory,
anti-diabetic, and anti-obesity properties. Recently, we also reported that Korean mistletoe extract (KME) improves
endurance exercise in mice, suggesting its beneficial roles in enhancing the capacity of skeletal muscle.
Methods: We examined the expression pattern of several genes concerned with muscle physiology in C2C12
myotubes cells to identify whether KME inhibits muscle atrophy or promotes muscle hypertrophy. We also
investigated these effects of KME in denervated mice model.
Results: Interestingly, KME induced the mRNA expression of SREBP-1c, PGC-1α, and GLUT4, known positive
regulators of muscle hypertrophy, in C2C12 cells. On the contrary, KME reduced the expression of Atrogin-1, which
is directly involved in the induction of muscle atrophy. In animal models, KME mitigated the decrease of muscle
weight in denervated mice. The expression of Atrogin-1 was also diminished in those mice. Moreover, KME
enhanced the grip strength and muscle weight in long-term feeding mice.
Conclusions: Our results suggest that KME has beneficial effects on muscle atrophy and muscle hypertrophy.
Background
Muscle atrophy is a feature of aging, starvation, cancer,
diabetes, muscle denervation, and other physical condi-
tions that limit muscle use [1]. The decrease of muscle
amount in the human body is considered as a symptom of
the disorder. With the increase of average life expectancy,
the number of cancer and diabetes patients has also
increased. Thus, the importance of maintaining muscle
mass is increasing. Although muscle atrophy occurs fre-
quently, there are no common clinical therapies to prevent
or repress the muscle atrophy in human cases to date [2].
Over the last few decades, the mechanisms related to
muscle mass decrease have not been clearly elucidated.
Many research studies were undertaken to find the
molecular mechanisms responsible for muscle mass
decrease and increase. However, recent studies strongly
support the idea that there are specific signaling
pathways regulating the muscle weight increase and
decrease [3]. Based on the recent reports, muscle mass
regulation is closely related to the PI3K/Akt pathway [4].
In the case of muscle hypertrophy, it is generally known
that increasing muscle mass is not because of an
increased number of muscle cells but because of an
increased amount of intracellular protein [5]. In the case
of muscle atrophy, the decreasing muscle mass is the op-
posite of muscle hypertrophy—decreased proteins in
muscle cells [6]. People called the genes that regulate
this specific, muscle mass decreasing mechanism Murf1
and Atrogin-1 [7]. These genes are closely linked with
protein ubiquitination [8, 9]. Nowadays, the aims of
studies regarding muscle atrophy and therapy for muscle
diseases are to find the unknown molecules or mecha-
nisms regulating Murf1 and Atrogin-1. Murf1 and
Atrogin-1 are members of the E3 ubiquitin ligase family
[10, 11]. The targets of these E3 proteins are intimately
involved with maintaining the structure of muscle cells
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and the construction of muscle [12]. It was also
proven that these E3 ubiquitin ligases are regulated
by the MAPK signaling pathway, including FoxO [13].
These genes stimulating muscle mass decrease are re-
pressed by the MAPK signaling pathway and, are acti-
vated by FoxO [14]. In the case of muscle
hypertrophy, previous studies verified that the Akt/
mTOR signaling pathway is the main signaling path-
way that regulates the muscle mass increase [15]. The
Akt/mTOR pathway is affiliated with several other
intracellular signaling pathways and key molecules for
survival, proliferation, stimulation of the cell cycle,
and many metabolic regulators [16, 17].
Mistletoe is a semi-parasitic plant that has been uti-
lized as a traditional medicine in many countries to treat
various human illnesses [18, 19]. In particular, Korean
mistletoe (Viscum album coloratum) has been widely
studied in the last decades since the report that it has a
anticancer activity [20]. It has been reported that Korean
mistletoe extract (KME) has a variety of effects on bio-
logical functions, demonstrating anti-tumor, anti-
oxidant, anti-diabetes, and anti-obesity benefits, and
promotes the extension of lifespan [21–23]. In addition,
we have recently reported that KME improved the
endurance capacity in mice by enhancing mitochondrial
activity [24]. In the treadmill and swimming tests, KME-
treated mice showed an increased exercise capacity
compared to chow-fed control mice. Therefore, it is
conceivable that KME also has beneficial functions in
enhancing the capacity of skeletal muscle in mice.
In this study, we discovered that KME can induce the
phosphorylation of Akt signaling pathway. Therefore, we
hypothesized that the increase and decrease of muscle
mass can be regulated by KME. Murf1 and Atrogin-1
were chosen as target genes to identify the inhibitory
effect of KME in muscle atrophy. We treated mouse
myoblast C2C12 cells with KME, and adopted an artifi-
cially induced muscle atrophy condition (denervation)
[25] in mice to validate its effects in vivo.
Methods
Preparation of KME
Korean mistletoe extract (KME) was supplied by Daeho
Corporation (Hwasung, Korea). Summarized manufac-
turing process is as follows. The leaves, twigs, and fruits
of Korean Mistletoe plants were homogenized in 7 vol-
umes of distilled water, using a blender. The homoge-
nized Korean Mistletoe extracts were stirred for 8 h at
100 °C. Then, secondary extraction was performed with
4 volumes of distilled hot water and filtered with 1 μm
Whatman™ filter paper. After filtration, the mistletoe ex-
tract was evaporated in vacuum condition and stored at
4 °C until use.
Reagents and antibodies
Dulbecco’s modified Eagle’s medium (DMEM), fetal
bovine serum, and penicillin/streptomycin were pur-
chased from GIBCO (Thermo Fisher Scientific,
Waltham, MA, USA). Anti-phospho-Akt, anti-total Akt,
anti-phospho-Foxo and anti-Foxo antibodies were pur-
chased from Cell Signaling Technology, Inc. (Danvers,
MA, USA). Anti-mouse HRP and anti-rabbit HRP were
purchased from Thermo Scientific. PVDF membranes
and SuperSignal® West Pico and West Femto
Chemiluminescent Substrate for western blotting
analysis were purchased from Thermo Scientific, and X-
ray films from AGFA (Mortsel, Belgium). SYBR Green
Master Mix for the real-time PCR analysis was pur-
chased from Applied Biosystems (Foster City, CA, USA).
Cell culture
The mouse muscle cell line C2C12 (mouse myoblast cell
line) was obtained from ATCC (American Type Culture
Collection, Manassas, VA, USA). C2C12 cells were
cultured in DMEM supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin, at 37 °C, and in
5% CO2 and 95% humidified air. Before treatment of
KME, C2C12 cells were moved to six-well plates and
incubated overnight. Cells were then cultured, with the
medium containing 2% horse serum, and incubated for
64 h to induce differentiation of the C2C12 cells. After
differentiation, KME (100 μg/ml) was treated for 16 h to
stimulate cells.
Animals
Five-week-old, specific-pathogen-free, male ICR mice
were purchased from Dae-Han Laboratory Animal Re-
search Center Co. Ltd (Seoul, Korea). Mice were cared
for in the Laboratory of Animal Experiment, Institute of
Bioscience, Handong Global University (Pohang, Korea).
Mice were maintained in single cages with 12 h light–
12 h dark cycles, and were used after 7 days had passed
since their arrival. All of the animal experiments were
approved by the Ethics Review Committee of the
Handong Global University.
Preparation of cell lysate and western blot analysis
C2C12 cells were prepared for western blotting to detect
phospho-Akt, total Akt, and β-actin expression. The
cells were washed with cold PBS twice before harvesting.
Cells were harvested in 150 μl of cell lysis buffer pur-
chased from iNTRON Biotechnology Inc. (Daejeon,
Korea). After collecting the cells, the samples were
boiled for 10 min in 95 °C. After boiling, samples were
centrifuged at 13,000 rpm for 10 min at 4 °C. The con-
centration of collected supernatants was determined by
a BCA assay kit (Thermo Scientific).
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The protein samples (30 μg) were loaded on the 8–
10% polyacrylamide gel and blotted on a PVDF mem-
brane in transfer buffer at 200 mA, 2 h after electro-
phoresis. The blots were blocked with 10% milk in PBST
(0.1% Tween-20 in PBS) for 1 h, at room temperature.
The blots were incubated with antibodies specific to
phospho-Akt (1:1000), Akt(1:1000), phospho-
Foxo(1:1000), Foxo(1:1000) and β-actin (1:2000), over-
night at 4 °C. The blots were washed three times using
PBST, and then incubated with the horseradish
peroxidase-conjugated secondary antibody (1:10000) for
1 h, at room temperature. After incubation, the blots
were washed again with PBST. After washing, the blots
were detected with SuperSignal West Pico or West
Femto Chemiluminescent Substrate, using X-ray film.
Denervation and KME treatment
Six-week-old, male ICR mice were used for the denerv-
ation experiments. The right leg was denervated by cut-
ting the sciatic nerve in middle of the leg under
anesthesia. KME (200 mg/kg or 500 mg/kg) was given to
the mice twice a day, every day, for 2 weeks, through
oral administration. After this period of time, whole
body grip strength was determined using a grip strength
machine, with tests repeated five times. Mice were sacri-
ficed and the quadricepses of the mice were collected
and directly used for the experiments or keep at −80 °C
for future use.
Induction of hypertrophy
For hypertrophy, six-week–old, male ICR mice had ac-
cess to water and the chow contained KME (0.25% KME
extract was included) that was ad libitum for 4 weeks.
After the 4 weeks, the whole body grip strength was
tested using a grip strength machine, and tests were re-
peated five times. Mice were then sacrificed and
quadricepses were harvested and directly used for the
experiments or keep at −80 °C for the future
experiments.
Preparing RNA and protein samples from quadricepses
The isolated quadricepses were used in preparing RNA sam-
ples for real-time PCR analysis and protein samples for
western blotting analysis. PRO-PREP™ lysis buffer was used
for preparing protein samples from the quadricepses: the
muscle samples were homogenized in the lysis buffer. After
homogenization, the samples were centrifuged at
13,000 rpm for 15 min at 4 °C. The concentrations of sam-
ples were determined by a BCA assay kit. Total RNA was
extracted using the easy-spin™ RNA extraction kit (iNtRON
Biotechnology Inc., Seongnam-si, Gyeonggi-do, Korea).
Muscle samples were homogenized in the easy-spin™ RNA
extraction buffer and the other procedures were performed
according to the manufacturer’s instructions.
Real-time PCR analysis
Total RNA (1 μg) was used for cDNA synthesizing with
SuperScript™ II Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA) and an oligo(dT) primer. Real-time
PCR was performed using the 7500 sequence detection
system (Applied Biosystems) with SYBR Green Master
Mix (Thermo Scientific) and ROX™ Reference Dye (Invi-
trogen). The amount of each reagent and the PCR con-
dition used was according to the manufacturers’
instructions. Relative mRNA expression levels were
determined using the ΔΔCt value. β-Actin was used for
the endogenous loading control. Experiments were
performed with specific primer sequences (Table 1).
Analysis of skeletal muscle fiber
Skeletal muscle tissues (quadriceps) were fixed overnight
in 4% formaldehyde at room temperature. Then, skeletal
muscle samples were frozen in optimal cutting
temperature (OCT) and sectioned at 5 μm for
hematoxylin and eosin (H&E) staining. Images were cap-
tured with Motic BA300 microscope and ImageJ soft-
ware (developed by Wayne Rasband, National Institute
of Health, Bethesda, MD) was used for analysis.
Statistical analysis
Figures were expressed using GraphPad prism 5 software
(GraphPad Software, Inc., CA, USA). Data were pre-
sented as mean ± S.D. and analyzed by one-way ANOVA
t-test. P values < 0.05 were considered as significant.
Results
KME treatment induces the activation of the PI3K/Akt
pathway in cells
To investigate the muscle atrophy inhibition and muscle
hypertrophy stimulation by KME, we first checked
whether the PI3K/Akt pathway is activated in C2C12 cell
lines. KME treated cells, and a non-treated control cells
were also established. In the KME-treated cells, higher
phosphorylation of Akt was detected compared with
Table 1 Real-time PCR primer sequences
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non-treated control cells (Fig. 1). These data suggest that
KME has an effect on the regulation of the muscle mass
through the activation of the Akt/mTOR signaling
pathway.
KME treatment regulates other metabolic pathways in
cells
To investigate the effect of KME on muscle mass regula-
tion further, we also examined the phosphorylation of
FoxO in C2C12 cells. FoxO is a known key molecule of
muscle atrophy due to its role in the activation of pro-
tein degradation [13]: FoxO induces muscle atrophy by
stimulating the E3 ubiquitin ligases Murf1 and Atrogin-
1 [26]. Compared to the non-treated control cells, the
KME-treated cells showed increased phosphorylation of
FoxO (Fig. 2). These data also support our previous ob-
servation that KME could induce the phosphorylation of
AMPK, which is a repressor of FoxO.
KME treatment regulates muscle atrophy related gene
expression in cells
To determine the direct effect of KME in the regulation
of muscle atrophy, we checked the mRNA expression of
genes related to muscle atrophy in C2C12 cells. A real-
time PCR method was used to measure the expression
levels of Murf1 and Atrogin-1, so-called “atrogenes”. In
addition, the mRNA expression levels of PGC-1α,
GLUT4, and SREBP-1c, that regulate the expression of
Atrogin-1 and Murf1, were also examined. After 16 h,
the KME-treated group showed a decreased gene ex-
pression of Atrogin-1, compared to the non-treated
group (Fig. 3). On the contrary, the KME-treated group
showed increased mRNA expression of PGC-1α,
GLUT4, and SREBP-1c, compared to the non-treated
group (Fig. 4). These genes are related to the inhibition
of muscle atrophy and are related to the induction of
muscle hypertrophy [27–29]. These analyses
Fig. 1 Activation of the Akt signaling pathway by KME (Left) Relative
phosphorylation of Akt (P-Akt) is shown. The concentration of KME was
100 μg/ml. (Right) The relative amount of phospho-Akt is shown. All the
samples were blotted against β-actin as a loading control. NT: non-treated
cells. P-values of < 0.05 and< 0.01 are indicated by * and **, respectively
Fig. 2 The effect of KME on the phosphorylation of FoxO.
Phosphorylation of FoxO (P-FoxO) by KME(100 μg/ml) treatment in
C2C12 cells. (Right) The relative amount of phospho-FoxO is indicated.
P-values of < 0.05 and < 0.01 are indicated by * and **, respectively
Fig. 3 The inhibition of muscle atrophy related gene expression by
KME (a) The relative amount of Atrogin-1 was measured after KME
treatment. The final concentration of KME was 100 μg/ml. b The
relative amount of Murf1 is shown. The mRNA expression levels were
compared to β-actin. Data are shown as means of the relative
expression levels ± SEM. P-values of < 0.05 and < 0.01 are indicated by *
and **, respectively
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demonstrate the multifunctional effects of KME in the
activation of Akt and AMPK signaling pathways.
KME lessens the decrease of muscle mass in denervated
mouse models
Based on our data from real-time RT-PCR in C2C12
cells, we hypothesized that KME might reduce muscle
atrophy in vivo, using the animal model. To validate this
hypothesis, we tried to selectively denervate the right
quadricepses of mice by amputating each right leg’s sci-
atic nerve. Denervation is a common method to induce
artificial muscle atrophy in the specific skeletal muscle.
In our study, we designated control group the PBS-
treated denervated group. After denervation, we treated
KME (200 mg/kg and 500 mg/kg) to the mice every 12 h
by oral gavage for 15 days. After 15 days of treatment,
KME treated mice showed decreased denervation in-
duced by muscle atrophy (Fig. 5a). In the mRNA expres-
sion levels monitored, Murf1 expression was not
affected by KME treatment. However, in the case of
Atrogin-1, KME (low fed) decreased the expression of
Atrogin-1 compared to the KME non-treated group
(Fig. 5b and c). These data suggest that KME might re-
press the artificial muscle decrease, and this effect is
closely related to the regulation of Atrogin-1 gene
expression.
KME increases muscle mass and grip strength in native
conditions
The reduction of muscle atrophy by KME led us to
hypothesize that KME might induce muscle hyper-
trophy. This hypothesis is based on the observation that
KME induces the upregulation of muscle atrophy related
genes and the activation of the Akt signaling pathway in
C2C12 cells. To evaluate the muscle hypertrophic effects
of KME in vivo, mice were allowed free access to control
chow or chow containing 0.3% or 1.5% KME for 4 weeks.
Compared to the control mice, the KME-containing
chow-fed mice showed increased whole body weights, a
higher weight of quadricepses, and increased grip
strengths in high KME-fed group (Fig. 6). These data
present the morphological indication that KME might
induce skeletal muscle hypertrophy in mice.
Fig. 4 The induction of muscle atrophy and hypertrophy related
gene expression by KME. a The relative amount of PGC-1α is shown.
b The relative amount of GLUT4 is shown. c The relative amount of
SREBP-1c is shown. All the analyses were performed after treatment
of KME at a final concentration of 100 μg/ml. The mRNA expression
levels were compared to β-actin. Data are shown as means of the
relative expression levels ± SEM. P-values of < 0.05 and < 0.01 are
indicated by * and **, respectively
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KME showed increased endurance in vivo
To validate the muscle hypertrophic effect of KME, the
treadmill and swimming pool tests were performed after
the feeding of control chow or KME-containing chow
over the 4 weeks. KME-containing chow-fed mice
showed increased swimming activity and elevated run-
ning times on the treadmill compared to the control
chow-fed mice (Fig. 7). In addition, skeletal muscle area
and diameter were also increased in KME-fed mice
(Fig. 8).
Discussion
Previous reports regarding muscle atrophy and hyper-
trophy have shown that muscle atrophy induced by vari-
ous kinds of mechanisms—such as fasting, illness
(cancer and diabetes), and muscle disuse—all result in
similar specific increases of mRNA expression [30, 31].
These similar specific genes are called “atrogenes” [32].
In this present study, we showed that these genes
(Murf1 and Atrogin-1) are downregulated by KME treat-
ment, suggesting its effect on the inhibition of muscle
atrophy. Atrogin-1 is known to promote the degradation
of MyoD and elF3f [33]: MyoD is an important tran-
scription factor of muscle and elF3f is one of the enhan-
cer proteins of protein synthesis [34, 35]. Atrogin-1
degrades both of these proteins resulting in muscle atro-
phy. Murf1 regulates muscle structural proteins like
troponin 1 and myosin [11, 36].
Mistletoe extracts were already used in broad spec-
trums as remedying agents [37, 38]. Based on the activa-
tion of the Akt signaling pathway and AMPK, we
speculated that mistletoe extract could regulate cellular
signaling involved in the regulation of muscle mass be-
cause these pathways are closely related to muscle atro-
phy and hypertrophy. Consistent with our prediction, we
found that KME inhibits “atrogene” expression in
C2C12 cells. Thus, we adopted an in vivo animal model
to validate our observation in myotubes. In a subsequent
study, we used a well-known method to induce muscle
atrophy called denervation [39, 40]. After denervation of
the sciatic nerves of the control mice, Murf1 and
Atrogin-1 mRNA expression were increased, and the
muscle mass were decreased. Grip strength was also re-
duced in the control mice. Compared with these control
mice, KME treated mice showed a decreased expression
of Atrogin-1 and Murf1, increased muscle mass, and
greater grip strength.
Fig. 5 Decreased muscle atrophy in KME-fed denervated mice (a)
The weight of quadricepses is shown. b The relative amount of
Atrogin-1 is shown. c The relative amount of Murf1 is shown. Data
are shown as means of the relative expression levels ± SEM; n = 5
per group. P-values of < 0.05 and < 0.01 are indicate by * and **,
respectively. KME(low) : 0.3%, KME(high) : 1.5%
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We also investigated other signaling molecules in-
volved in muscle atrophy repression and muscle hyper-
trophy in KME-treated cells and mice. However, there
were no significant differences in the phosphorylation of
mTOR and S6k by KME [41, 42]. Recently, it we re-
ported that mTOR promotes muscle atrophy in dener-
vated mice through the activation of FoxO and E3
ubiquitin ligases [43]. This is exactly opposite to the
current paradigm depicting the function of mTOR in
muscle hypertrophy and muscle atrophy [44]. The
current dogma of mTOR functionality is the stimulation
of muscle hypertrophy in skeletal muscle [45]. There-
fore, there are still controversies about the role of
mTOR in muscle physiology. Further studies are needed
to figure out the relationship between the mTOR signal-
ing pathway and the induction of muscle atrophy.
Another well-known signaling pathway involved in
muscle atrophy is the NF-κB one [46]. This signaling
pathway is also closely related with inflammation [47]. It
was also reported that inflammation was repressed by
mistletoe extract [48]. Further studies are required to
elucidate whether KME treatment affects inflammation
and NF-κB signaling in the inhibition of muscle atrophy.
Extending from the induced muscle atrophy model in-
vestigated, we also tried to test whether KME induce
muscle hypertrophy in mice skeletal muscle. It is proven
that an inhibition of muscle atrophy is associated with
muscle hypertrophy [7]. We also proved this kind of
hypertrophic effect with KME treatment in this study.
Without any artificial induction of muscle atrophy, mice
that fed on KME for 4 weeks showed increased muscle
mass and grip strength. These results suggest that KME
affects not only muscle atrophy but also muscle hyper-
trophy. Furthermore, our results also imply that KME
can regulate both atrophy and hypertrophy independ-
ently. It was confirmed by the endurance tests that KME
regulates muscle hypertrophy independent of muscle at-
rophy [49]. KME-containing chow-fed mice showed in-
creased endurance compared to the control chow-fed
mice. Muscle hypertrophy and increased endurance were
closely related with the muscle fiber type switching [50,
51]. It is noteworthy that the study on the type switching
of the muscle fiber might give us another molecular clue
of the effects of KME in muscle regulation. In addition,
a comparative study on the effects of KME in cardiac
muscle and skeletal muscle is required—several reports
Fig. 6 Physical changes in KME-fed mice (a) The grip strength of
each chow-fed mouse is presented. b The weights of quadricepses
are shown. c Whole body weights are shown. All the mice were fed
chow for 4 weeks and analyses were done after the 4 weeks. Data
shown are mean ± S.D.; n = 5 per group. P-values of < 0.05 and
< 0.01 are indicate by * and **, respectively. KME(low) : 0.3%,
KME(high) : 1.5%
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demonstrated that the function of the mTOR signaling
pathway is different between skeletal muscle and cardiac
muscle [52].
In conclusion, the results of this study suggest that
KME has positive regulatory effects on the maintenance
of muscle mass. Our data shows the possibilities that
KME could be used as a potential therapy for muscle at-
rophy in human cases.
Conclusions
Korean mistletoe extracts have inhibitory effects on
muscle atrophy and stimulatory effects on muscle hyper-
trophy in C2C12 cells and denervated mice. These find-
ings suggest that Korean mistletoe might be a potential
candidate as a functional food promoting the restoration
from muscle atrophy.
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